Web Date: September 19, 2006
Pfizer Licenses TransTech Compounds
Pfizer has signed a licensing agreement with TransTech Pharma for the development and commercialization of small- and large-molecule compounds under development by TransTech for the treatment of Alzheimer's disease and other diseases.
The compounds target the receptor for advanced glycation end products (RAGE). The most advanced of the compounds are TTP488, an orally available small-molecule candidate that has completed Phase II clinical trials in patients with Alzheimer???s disease and diabetic nephropathy, and TTP4000, . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society